ANGO logo

ANGO
Angiodynamic Inc

1,066
Mkt Cap
$466.61M
Volume
227,154.00
52W High
$13.99
52W Low
$8.27
PE Ratio
-16.67
ANGO Fundamentals
Price
$11.22
Prev Close
$11.20
Open
$11.34
50D MA
$11.53
Beta
1.04
Avg. Volume
903,575.45
EPS (Annual)
-$0.8321
P/B
2.65
Rev/Employee
$433,330.37
$364.75
Loading...
Loading...
News
all
press releases
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options...
Business Wire·3d ago
News Placeholder
More News
News Placeholder
Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings
VCYT heads into Q4 earnings with rising estimates, strong Decipher and Afirma volumes, and revenues seen up nearly 17% year over year.
Zacks·6d ago
News Placeholder
Bastion Asset Management Inc. Buys 304,960 Shares of AngioDynamics, Inc. $ANGO
Bastion Asset Management Inc. boosted its position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 31.8% in the third quarter, according to its most recent disclosure with the Securities and...
MarketBeat·6d ago
News Placeholder
Waters Q4 Earnings Surpass Estimates, Revenues Increase Y/Y
WAT tops Q4 estimates as revenues rise 7% Y/Y, with strong Pharma and Europe growth, and upbeat 2026 sales and earnings outlook.
Zacks·9d ago
News Placeholder
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth
DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.
Zacks·9d ago
News Placeholder
Essex Investment Management Co. LLC Increases Holdings in AngioDynamics, Inc. $ANGO
Essex Investment Management Co. LLC lifted its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 41.9% during the third quarter, according to its most recent 13F filing with...
MarketBeat·12d ago
News Placeholder
AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat.com...
MarketBeat·15d ago
News Placeholder
Does AngioDynamics (ANGO) Have the Potential to Rally 92.15% as Wall Street Analysts Expect?
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·16d ago
News Placeholder
AngioDynamics (ANGO) Down 3.9% Since Last Earnings Report: Can It Rebound?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·17d ago
News Placeholder
AngioDynamics and The PERT Consortium Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options...
Business Wire·17d ago
<
1
2
...
>

Latest ANGO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.